In the last trading session, 8.85 million Calidi Biotherapeutics Inc (AMEX:CLDI) shares changed hands as the company’s beta touched 1.12. With the company’s per share price at $1.05 changed hands at $0.29 or 38.49% during last session, the market valuation stood at $27.21M. CLDI’s last price was a discount, traded about -1500.0% off its 52-week high of $16.80. The share price had its 52-week low at $0.58, which suggests the last value was 44.76% up since then. When we look at Calidi Biotherapeutics Inc’s average trading volume, we note the 10-day average is 1.36 million shares, with the 3-month average coming to 1.91 million.
Calidi Biotherapeutics Inc (AMEX:CLDI) trade information
Instantly CLDI was in green as seen at the end of in last trading. With action 59.07%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -8.70%, with the 5-day performance at 59.07% in the green. However, in the 30-day time frame, Calidi Biotherapeutics Inc (AMEX:CLDI) is -8.70% down. Looking at the short shares, we see there were 0.59 million shares sold at short interest cover period of 0.88 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5.5, meaning bulls need an upside of 80.91% from its current market value. According to analyst projections, CLDI’s forecast low is 2 with 9 as the target high. To hit the forecast high, the stock’s price needs a -757.14% plunge from its current level, while the stock would need to soar -90.48% for it to hit the projected low.
Calidi Biotherapeutics Inc (CLDI) estimates and forecasts
Data shows that the Calidi Biotherapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -37.13% over the past 6 months, a 74.10% in annual growth rate that is considerably higher than the industry average of 15.90%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
The 2025 estimates are for Calidi Biotherapeutics Inc earnings to increase by 78.64%.
CLDI Dividends
Calidi Biotherapeutics Inc is expected to release its next quarterly earnings report in March.
Calidi Biotherapeutics Inc (AMEX:CLDI)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 18.16% of Calidi Biotherapeutics Inc shares while 2.71% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 3.31%. There are 2.71% institutions holding the Calidi Biotherapeutics Inc stock share, with RED WAVE INVESTMENTS LLC the top institutional holder. As of 2024-06-30, the company held 1.1723% of the shares, roughly 0.62 million CLDI shares worth $0.12 million.
CPR INVESTMENTS INC. holds the second largest percentage of outstanding shares, with 1.0511% or 0.56 million shares worth $0.11 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were Fidelity Extended Market Index Fund and Bridgeway Funds Inc-Ultra Small Company Market Fund . With 30.96 shares estimated at $32510.0 under it, the former controlled 0.11% of total outstanding shares. On the other hand, Bridgeway Funds Inc-Ultra Small Company Market Fund held about 0.04% of the shares, roughly 10.0 shares worth around $10499.0.
